News

blood pressure monitors stroke treatment devices hypertenion therapies cath lab

A new way of using blood pressure-lowering medications could prevent more than a fourth of heart attacks and ...

According to a study of diabetic patients who underwent revascularization for multivessel coronary artery...

A new study demonstrated that some patients may not need to receive prolonged anti-clotting therapy after drug-...

cath lab clinical trial study pharmaceuticals antiplatelet therapy arctic

Patients who do not experience a major cardiac event in the first year after receiving drug-eluting stent (DES) may not need to receive prolonged dual ...

xience prime xpedition V antiplatelet stents eluting clinical trial study cath

Abbott announced it plans to initiate a randomized, controlled trial in the United States to evaluate the use...

PDI, Inc. and Transgenomic, Inc. announced the signing of a U.S. collaboration agreement to commercialize CardioPredict, a molecular diagnostic test developed by Transgenomic. CardioPredict is a...

Cath Lab pharmaceuticals clinical trial study CNIC spain icahn heart attack

Early treatment of heart attack patients with an inexpensive beta-blocker drug called metoprolol, while in transit to the hospital, can significantly reduce damage to the heart during a...

The Cardiovascular Research Foundation (CRF) announced the late breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2013...

A study by Cutting Edge Information found that pharmaceutical companies measure cost per patient per month to allow trials of different sizes and durations to be compared easily. This measurement...

Icahn School of Medicine at Mount Sinai PARIS Study Antiplatelet Therapy PCI

Lead study investigators from Icahn School of Medicine at Mount Sinai presented their Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) study findings at the ESC...

Aggredyne Inc., has received ISO 13485 certification for its quality control program related to the manufacture of the AggreGuide family of platelet function analyzers.

Decision Resources forecasts that Bayer/Janssen's Xarelto will be the sales-leading therapy among the novel oral anticoagulants in the combined venous thromboembolism (VTE) markets. Xarelto...

Atherotech Diagnostics Lab has added three new genetic tests to its cardiometabolic test offering: warfarin sensitivity, Plavix sensitivity and the thrombophilia risk test.

 

Among patients with prehypertension and coronary artery disease, use of the renin (an enzyme secreted by the kidneys) inhibitor aliskiren, compared with placebo, did not result in improvement or...

Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non–ST-segment elevation...

September 5, 2013 — ITC Nexus Holding Co., a company in hemostasis management and point-of-care (POC) testing, announced it has acquired Accumetrics, a specialist in assessing patient response to...

August 5, 2013 — AstraZeneca announced results from a new sub-analysis of the PLATO study that evaluated the incidence of stent thrombosis in patients with acute coronary syndrome (ACS).

Merck announced that the New Drug Application (NDA) for its investigational anti-thrombotic medicine, vorapaxar, has been accepted...